Schwaneck, Eva C. http://orcid.org/0000-0003-1935-2092
Krone, Manuel
Kreissl-Kemmer, Sonja
Weißbrich, Benedikt
Weiss, Johannes
Tony, Hans-Peter
Gadeholt, Ottar
Schmalzing, Marc
Geier, Andreas
Article History
Received: 8 May 2018
Revised: 5 September 2018
Accepted: 10 September 2018
First Online: 20 September 2018
Compliance with ethical standards
:
: E.C. Schwaneck, H-P. Tony, O. Gadeholt, and M. Schmalzing have received travel grants, speaker’s fees, research grants, or compensation for board membership and consultancies from Celgene AbbVie, Baxalta (Shire), Chugai, Roche, Janssen, Pfizer, MSD, UCB, Novartis, and Lilly. S. Kreissl-Kemmer received a travel grant from Daiichi Sankyo. M. Krone has no competing interests. J. Weiss has received travel grants, speaker’s fees, or compensation for board membership and consultancies from AbbVie, BMS, and Gilead. A. Geier has received travel grants, speaker’s fees, research grants, or compensation for board membership and consultancies from AbbVie, BMS, Gilead, Janssen, Falk, Sequana, and Novartis. B. Weissbrich has no competing interests.